249 related articles for article (PubMed ID: 10638596)
21. Rezulin to be withdrawn from the market.
Diabetes Technol Ther; 2000; 2(2):289. PubMed ID: 11469272
[No Abstract] [Full Text] [Related]
22. Hepatic injury due to troglitazone.
Malik AH; Prasad P; Saboorian MH; Thiele DL; Malet PF
Dig Dis Sci; 2000 Jan; 45(1):210-4. PubMed ID: 10695637
[No Abstract] [Full Text] [Related]
23. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.
Menon KVN ; Angulo P; Lindor KD
Am J Gastroenterol; 2001 May; 96(5):1631-4. PubMed ID: 11374713
[TBL] [Abstract][Full Text] [Related]
24. A novel antidiabetic drug, troglitazone--reason for hope and concern.
Imura H
N Engl J Med; 1998 Mar; 338(13):908-9. PubMed ID: 9516229
[No Abstract] [Full Text] [Related]
25. Troglitazone-induced hepatic failure leading to liver transplantation. A case report.
Neuschwander-Tetri BA; Isley WL; Oki JC; Ramrakhiani S; Quiason SG; Phillips NJ; Brunt EM
Ann Intern Med; 1998 Jul; 129(1):38-41. PubMed ID: 9652998
[TBL] [Abstract][Full Text] [Related]
26. Troglitazone (Rezulin) and hepatic injury.
Faich GA; Moseley RH
Pharmacoepidemiol Drug Saf; 2001; 10(6):537-47. PubMed ID: 11828837
[TBL] [Abstract][Full Text] [Related]
27. [Clinical effect and side effect of troglitazone].
Toyota T; Ueno Y
Nihon Rinsho; 2000 Feb; 58(2):376-82. PubMed ID: 10707561
[TBL] [Abstract][Full Text] [Related]
28. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
29. Thiazolidinedione hepatotoxicity: a class effect?
Tolman KG
Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828
[TBL] [Abstract][Full Text] [Related]
30. Drug recalls underscore safety concerns.
Greene HL
Health News; 2000 May; 6(5):4. PubMed ID: 10851966
[No Abstract] [Full Text] [Related]
31. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
32. An autopsy case of troglitazone-induced fulminant hepatitis.
Shibuya A; Watanabe M; Fujita Y; Saigenji K; Kuwao S; Takahashi H; Takeuchi H
Diabetes Care; 1998 Dec; 21(12):2140-3. PubMed ID: 9839107
[TBL] [Abstract][Full Text] [Related]
33. How should patients taking the discontinued diabetes drug troglitazone be managed?
Reddy SS
Cleve Clin J Med; 2000 Jun; 67(6):401-2, 455. PubMed ID: 10860221
[No Abstract] [Full Text] [Related]
34. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
[TBL] [Abstract][Full Text] [Related]
35. Substituting for troglitazone (Rezulin).
Med Lett Drugs Ther; 2000 Apr; 42(1076):36. PubMed ID: 10803176
[No Abstract] [Full Text] [Related]
36. [The development of thiazolidinedione drugs as anti-diabetic agents].
Kuzuya T
Nihon Rinsho; 2000 Feb; 58(2):364-9. PubMed ID: 10707559
[TBL] [Abstract][Full Text] [Related]
37. Severe but reversible hepatitis induced by troglitazone.
Schiano T; Dolehide K; Hart J; Baker AL
Dig Dis Sci; 2000 May; 45(5):1039-42. PubMed ID: 10795774
[No Abstract] [Full Text] [Related]
38. Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings.
Li H; Heller DS; Leevy CB; Zierer KG; Klein KM
J Diabetes Complications; 2000; 14(3):175-7. PubMed ID: 10989325
[TBL] [Abstract][Full Text] [Related]
39. Deterioration of rheumatoid arthritis with troglitazone: a rare and unexpected adverse effect.
Sakurai A; Hashizume K
Arch Intern Med; 2000 Jan; 160(1):118-9. PubMed ID: 10632316
[No Abstract] [Full Text] [Related]
40. Fatal hepatotoxicity associated with troglitazone.
Vella A; de Groen PC; Dinneen SF
Ann Intern Med; 1998 Dec; 129(12):1080. PubMed ID: 9867776
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
